What happened
Dongbu updated a previously disclosed supply contract with Royal Canin Korea Ltd., now worth US$64M, about 5.86% of its recent annual revenue, running through Aug 2026.
For context, this single contract equals about 5.86% of the company's most recent annual revenue.
| Counterparty | Royal Canin Korea Ltd. |
|---|---|
| Contract value | US$64M |
| vs. recent revenue | 5.86% |
| Through | Aug 2026 (from Jan 2024) |
| Filed | 2026-06-26, [Amended] Supply contract signed |
| Source | DART rcept 20260626800902 → open original filing |
Source: DART. Information only, not investment advice.